第一章 總則 第一條 為規範北京鷹瞳科技發展股份有限公司（以下簡稱「公司」）董事及高級管理 人員的產生，優化董事會組成，完善公司治理結構，根據《中華人民共和國公司法》 （以下簡稱「《公司法》」）、《香港聯合交易所有限公司證券上市規則》（以下簡稱「《上 市規則》」）、《上市規則》附錄C1所載的《企業管治守則》等相關法律、法規、規範性 文件及H股發行後適用的《北京鷹瞳科技發展股份有限公司章程》（以下簡稱「《公司 章程》」），依照董事會決議，公司特設立董事會提名委員會，並結合公司實際，制定 本《北京鷹瞳科技發展股份有限公司董事會提名委員會工作細則》（以下簡稱「本細 則」）。 第二條 董事會提名委員會是公司董事會下設的專門工作機構，主要職責是對公司 董事（包括獨立非執行董事）及高級管理人員的選擇、選擇標準和程序進行研究並向 董事會提出意見和建議。 本細則所稱的高級管理人員，是指公司的總經理、董事會秘書、財務總監以及由董 事會明確聘任為公司高級管理人員的其他人員。本細則所稱「總經理」即《公司法》所 稱「經理」。 – 1 – Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限 ...

Core Viewpoint - Beijing Eagle Eye Technology Development Co., Ltd. (2251.HK) anticipates achieving profitability for the six months ending June 30, 2025, following a net loss of approximately 81.5 million yuan in the same period of 2024, with a projected net profit not exceeding 500,000 yuan for 2025 [1] Group 1: Operational Efficiency - The company has implemented AI-driven solutions across its entire business chain, enhancing operational efficiency from customer acquisition to backend services [1] - Human-machine collaboration has shortened business turnaround cycles and improved resource input-output ratios [1] Group 2: Cost Control - The company has transitioned from "passive cost-cutting" to "active efficiency enhancement" through AI management tools [1] - Dynamic monitoring and precise control of core cost items such as procurement, labor, and operations have effectively reduced the proportion of non-core expenditures [1] Group 3: Financial Management - Strengthened credit period management has accelerated accounts receivable turnover, reducing capital occupation costs and promoting financial stability [1] Group 4: Future Outlook - The financial data provided is preliminary and has not been reviewed by independent auditors or confirmed by the audit committee, indicating potential adjustments before the final mid-term performance figures are published [1] - The company plans to release the unaudited consolidated results for the mid-term of 2025 by the end of August 2025, in accordance with listing rules [1]

Core Insights - The Chinese AI + medical imaging industry is rapidly developing, with a market size projected to reach 7.6 billion yuan in 2024, representing a year-on-year growth of 109.94% [1][11] - AI technology is capable of quickly identifying small lesions from vast amounts of imaging data, facilitating precise early screening for various diseases and providing significant diagnostic support for doctors [1][11] - The product types in AI medical imaging are diversifying, with a trend towards integrated hardware and software solutions becoming the preferred choice for medical institutions [1][11] Industry Overview - AI + medical imaging refers to the use of AI technologies, such as deep learning and computer vision, to analyze and process medical images (e.g., X-rays, CT scans, MRIs, ultrasounds) to assist doctors in disease diagnosis, treatment planning, and prognosis evaluation [1][4] - The core function includes auxiliary diagnosis, treatment planning, prognosis assessment, and early detection screening [1][4] Industry Value Chain - The upstream of the AI + medical imaging industry includes medical imaging equipment, chips, servers, storage devices, imaging acquisition and processing software, cloud services, network operation platforms, and algorithm and data platforms [4] - The midstream involves the development and manufacturing of AI + medical imaging technologies, while the downstream primarily serves medical institutions, health check centers, and research and educational institutions [4] Market Size - The market size of the Chinese medical imaging equipment industry is expected to reach 69.3 billion yuan in 2024, with a year-on-year growth of 9.83% [6] Relevant Policies - The Chinese government has issued several policy documents to support and regulate the development of the AI + medical imaging industry, emphasizing the optimization of medical device standards and the establishment of standardization organizations for AI and medical robotics [8][10] - The policies aim to accelerate approval processes, enhance innovation ecosystems, and improve international competitiveness [8][10] Key Companies and Performance - Major companies in the AI + medical imaging sector include United Imaging Healthcare, Wandong Medical, Mindray, and Shukun Technology, each leveraging unique strengths in hardware and AI software integration [13][15] - United Imaging Healthcare reported a revenue of 10.3 billion yuan in 2024, a decrease of 9.73% year-on-year, while its R&D investment increased by 17.84% to 2.261 billion yuan [15] - Shukun Technology focuses on providing comprehensive AI solutions for medical institutions, achieving significant market penetration with its innovative products [17] Industry Development Trends 1. The industry is expected to advance towards multi-modal data integration and deep learning, enhancing diagnostic accuracy and personalized treatment [20] 2. Applications of AI in medical imaging will expand from auxiliary diagnosis to full-process management, improving service efficiency and quality [21] 3. Regulatory frameworks will evolve to include data privacy protections and accountability mechanisms for AI-generated content [22]

鹰瞳科技-B(02251)发布公告，集团预期于2025年中期期间取得净溢利不超过人民币50万元，而于2024 年同期集团净亏损约人民币8150万元。 该变动主要由于(i)运营效率方面，公司采用AI驱动全业务链条，实现了从前端获客到后端服务的运营效 率提升，人机协同缩短业务周转周期，提升了资源投入产出比;(ii)成本管控方面，公司通过AI管理工 具，从"被动节流"到"主动提效"，对采购、人力、运营等核心成本项进行动态监测与精准调控，有效压 缩非核心支出占比;及(iii)财务管理方面，公司强化信用期管控，加速应收账款周转速度，减少资金占用 成本，促进财务稳健。 ...

Core Viewpoint - The company anticipates achieving a net profit of no more than RMB 500,000 by mid-2025, a significant improvement compared to a net loss of approximately RMB 81.5 million in the same period of 2024 [1] Group 1: Operational Efficiency - The company has implemented AI-driven solutions across its entire business chain, enhancing operational efficiency from customer acquisition to backend services [1] - Human-machine collaboration has shortened business turnaround cycles and improved resource input-output ratios [1] Group 2: Cost Control - The company has transitioned from "passive cost-cutting" to "active efficiency enhancement" through AI management tools [1] - Dynamic monitoring and precise control of core cost items such as procurement, labor, and operations have effectively reduced the proportion of non-core expenditures [1] Group 3: Financial Management - The company has strengthened credit period management, accelerating accounts receivable turnover and reducing capital occupation costs [1] - These measures promote financial stability and enhance overall financial management [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 基於其對本集團截至2025年6月30日止六個月（「2025年中期期間」）未經審核綜合管 理賬目的初步評估及本集團管理層現時可得的資料，董事會謹此通知本公司股東 （「股東」）及潛在投資者，本集團預期於2025年中期期間錄得淨溢利不超過人民幣50 萬元，而於2024年同期本集團淨虧損約人民幣81.5百萬元。該變動主要由於(i)運營 效率方面，公司採用AI驅動全業務鏈條，實現了從前端獲客到後端服務的運營效率 提升，人機協同縮短業務週轉週期，提升了資源投入產出比；(ii)成本管控方面，公 司通過AI管理工具，從「被動節流」到「主動提效」，對採購、人力、運營等核心成本 項進行動態監測與精準調控，有效壓縮非核心支出佔比；及(iii)財務管理方面，公 司強化信用期管控，加速應收賬款週轉速度，減少資金佔用成本，促進財務 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 董事會會議日期 北京鷹瞳科技發展股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 董事會將於2025年8月28日（星期四）舉行董事會會議，藉以考慮及批准（其中包括） 本公司及其附屬公司截至2025年6月30日止六個月之中期業績及其發佈，並考慮建 議派付中期股息（如有）。 承董事會命 北京鷹瞳科技發展股份有限公司 董事會主席 張大磊先生 香港，2025年8月18日 於本公告日期，董事會包括執行董事張大磊先生、王林女士、秦勇先生及魏宇博先 生；及獨立非執行董事武陽豐博士、黃彥林博士及吳浩然先生。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京鷹瞳科技發展股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,5 ...

截至本公告日期，目标公司集团主要在中国从事近视治疗仪的研发、生产及销售。 于本公告日期，该公司拥有目标公司70%股权。于收购事项完成后，目标公司将成为公司的全资附属公 司，而目标公司集团的财务业绩将继续并入该公司财务报表。 鹰瞳科技-B(02251)公布，于2025年7月30日，该公司拟向于湛先生及杨永康先生收购北京智瞳科技有限 公司30%股权，总代价为人民币2450万元。 公司认为，根据收购事项拟进行的建议收购目标公司余下30%股权将是实现集团创造更大价值战略，并 达成公司优化附属公司整体股权结构目标的重要一步。于收购事项完成后，目标公司将成为公司的全资 附属公司，且公司将对目标公司拥有全面控制权。 ...

截至本公告日期，目标公司集团主要在中国从事近视治疗仪的研发、生产及销售。 智通财经APP讯，鹰瞳科技-B(02251)公布，于2025年7月30日，该公司拟向于湛先生及杨永康先生收购 北京智瞳科技有限公司30%股权，总代价为人民币2450万元。 于本公告日期，该公司拥有目标公司70%股权。于收购事项完成后，目标公司将成为公司的全资附属公 司，而目标公司集团的财务业绩将继续并入该公司财务报表。 公司认为，根据收购事项拟进行的建议收购目标公司余下30%股权将是实现集团创造更大价值战略，并 达成公司优化附属公司整体股权结构目标的重要一步。于收购事项完成后，目标公司将成为公司的全资 附属公司，且公司将对目标公司拥有全面控制权。 ...